Pre-clinical evaluation of an in vitro selection protocol for the enrichment of transduced CD34+ cell-derived human dendritic cells

Gene Therapy

Volumn 8, Issue 18, 2001, Pages 1427-1435

  Evans, J T ^a   Cravens, P ^b   Gatlin, J ^a   Kelly, P F ^c   Lipsky, P E ^d   Garcia, J V ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Dendritic cells; DHFR selection; Gene therapy; Immunotherapy; Lentivirus vectors; MLV vectors

Indexed keywords

CD34 ANTIGEN; CYTOKINE; DIHYDROFOLATE REDUCTASE; DNA; FLT3 LIGAND; FOLIC ACID ANTAGONIST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 4; LEUCINE; TRIMETREXATE GLUCURONATE; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ARTICLE; AUTOIMMUNE DISEASE; CANCER; CELL DIFFERENTIATION; CELL MATURATION; CELL SELECTION; CISTRON; CLINICAL PROTOCOL; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; DRUG DELIVERY SYSTEM; EVALUATION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOTHERAPY; IN VITRO STUDY; INFECTION; LENTIVIRINAE; MURINE LEUKEMIA VIRUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; TRANSGENE;

ADULT; ANTIGENS, CD3; ANTIGENS, CD34; CELL DIFFERENTIATION; CELL SEPARATION; DENDRITIC CELLS; FLOW CYTOMETRY; GENETIC VECTORS; HIV; HUMANS; IMMUNOTHERAPY; LEUKEMIA VIRUS, MURINE; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 0034827532     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301530     Document Type: Article

References (43)

1. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity
2. + cells
3. Dendritic cells and the control of immunity
4. The dendritic cell system and its role in immunogenicity
5. Dendritic cells and immune-based therapies
6. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
7. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
8. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
9. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
10. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
11. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
12. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
13. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
14. Successful retroviral mediated transduction of a reporter gene in human dendritic cells: Feasibility of therapy with gene-modified antigen presenting cells
15. + cord blood cells under serum-free conditions
16. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus
17. High efficiency adenovirus-mediated gene transfer to human dendritic cells
18. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1)
19. + cells
20. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
21. + bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha
22. Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice
23. In vivo selection of retrovirally transduced hematopoietic stem cells
24. Cytokine prestimulation as a gene therapy strategy: Implications for using the MDR1 gene as a dominant selectable marker
25. Serial transplantation of methotrexate-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells
26. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea
27. v mice
28. Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers
29. Selection of retrovirally transduced hematopoietic cells using CD24 as a marker of gene transfer
30. Transfer and expression of the human multiple drug resistance gene into live mice
31. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1
32. A gene transfer strategy for making bone marrow cells resistant to trimetrexate
33. + cells
34. Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase
35. + cells
36. Highly efficient gene transfer into cord blood non-obese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein
37. + cells via human immunodeficiency virus-based gene transfer vectors
38. - Cell transduction via lentivirus-based gene transfer vectors
39. + cells in infant and adult human thymus
40. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors
41. Nucleoside transport in normal and neoplastic cells
42. Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine 5′-monophosphate
43. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection